Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients

doi:10.3969/j.issn.1673-8640.2024.01.008

Abstract

Abstract:

Objective To analyze the roles of thrombin-antithrombin complex（TAT），plasmin-alpha 2-antiplasmin inhibitor complex（PIC） and thromboelastography（TEG） for assessing coagulation function in tumor patients. Methods A total of 120 tumor patients in Cancer Hospital and Shenzhen Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College from January 2022 to August 2023 were enrolled as case group，and 30 healthy subjects were enrolled as control group. The difference of TAT，PIC and TEG were compared. Caprini score was used to compare the differences of TAT，PIC and TEG for the patients with different thrombus risk，and the differences of TAT，PIC and TEG with different tumor types were compared. The efficacy of TAT，PIC and TEG in coagulation function of tumor patients was analyzed by receiver operating characteristic（ROC） curve. Results In case group，TAT and PIC were higher than those in control group（P<0.05）. In thrombus extremely high-risk group，TAT and PIC were higher than those in medium/low-risk group（P<0.05）. TAT and PIC in patients with liver cancer，lung cancer，colon cancer and gastric cancer were increased（P>0.05）. The sensitivities of TAT，PIC and TEG in evaluating the hypercoagulable state of tumor patients were 85.0%，55.0% and 56.70%，and the specificities were 93.3%，81.7% and 70.0%，respectively. The areas under curves were 0.94，0.72 and 0.63，respectively. Conclusions TAT and PIC can determine abnormal coagulation function in tumor patients earlier than TEG，which can better indicate the hypercoagulabe state of tumor patients，and can be used as laboratory parameters for assessing coagulation function in tumor patients.

Key words: Thrombin-antithrombin complex, Plasmin-alpha 2-antiplasmin inhibitor complex, Thromboelastography, Coagulation function, Tumor

CLC Number:

R446.1

LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients[J]. Laboratory Medicine, 2024, 39(1): 43-46.

Figures/Tables 4

References 14

[1]	韩仁强, 武鸣, 缪伟刚, 等. 2015年江苏省恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2020, 29(2):81-89.
[2]	DI W, XU H, XUE T, et al. Advances in the prediction and risk assessment of lung cancer-associated venous thromboembolism[J]. Cancer Manag Res, 2021, 13:8317-8327. DOI PMID
[3]	HE L, LIN Q, ZHONG L, et al. Thromboelastography maximum amplitude as an early predictor of disseminated intravascular coagulation in patients with heatstroke[J]. Int J Hyperthermia, 2022, 39(1):605-610. DOI URL
[4]	中华医学会外科学分会. 中国普通外科围手术期血栓预防与管理指南[J]. 中华外科杂志, 2016, 54(5):321-327.
[5]	ZHOU K, ZHANG J, ZHENG Z R, et al. Diagnostic and prognostic value of TAT,PIC,TM,and t-PAIC in malignant tumor patients with venous thrombosis[J]. Clin Appl Thromb Hemost, 2020, 26:1076029620971041.
[6]	FALANGA A, MARCHETTI M, RUSSO L. The mechanisms of cancer-associated thrombosis[J]. Thromb Res, 2015, 135:S8-S11. DOI URL
[7]	蒋冬雪, 翟志敏. TAT、PIC、TM、t-PAIC四种分子标志物在弥散性血管内凝血早期诊断中的价值[J]. 中国科学技术大学学报, 2020, 50(4):474-478.
[8]	ROBERTSON L, BRODERICK C, YEOH S E, et al. Effect of testing for cancer on cancer- and venous thromboembolism(VTE)-related mortality and morbidity in people with unprovoked VTE[J]. Cochrane Database Syst Rev, 2021, 10(10):CD010837.
[9]	GRAZIOLI S, PACIARONI M, AGNELLI G, et al. Cancer-associated ischemic stroke:a retrospective multicentre cohort study[J]. Thromb Res, 2018, 165:33-37. DOI URL
[10]	LECI-TAHIRI L, ZHERKA-SARACINI H, TAHIRI A, et al. Bilateral internal jugular vein thrombosis due to malignant tumor[J]. J Med Case Rep, 2018, 12(1):42. DOI
[11]	LIN C Y, LIU W C, CHIANG M H, et al. Myasthenic crisis and late deep vein thrombosis follwing thymectomy in a patient with myasthenia gravis:a case reoort[J]. Medicine, 2020, 99(15):e19781. DOI URL
[12]	崔婵娟, 崔巍, 高佳, 等. 凝血酶-抗凝血酶复合物和纤溶酶-α2纤溶酶抑制物复合物优于D二聚体用于肿瘤患者血栓的诊断[J]. 中华检验医学杂志, 2019, 42(10):853-857.
[13]	NATSUM ED A M, UZUKA T, WATANABE J, et al. High incidence of deepvein thrombosis in the perioperative period of neurosurgical patients[J]. World Neurosurg, 2018, 112:e103-e112. DOI URL
[14]	曹盛吉, 冯丹, 吕明琪. 恶性肿瘤患者血栓分子标志物变化及临床意义[J]. 中国老年学杂志, 2020, 40(4):756-759.

组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	TEG
组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	R/min	K/min	Angle角/°	MA/mm
病例组	120	5.98±4.38	1.12±1.07	5.28±0.86	1.98±0.68	65.95±6.84	63.17±8.02
对照组	30	1.23±0.11	0.45±0.09	5.63±1.03	2.15±0.38	63.05±8.02	62.79±6.08
t值		11.87	3.51	1.72	1.83	1.92	0.29
P值		<0.01	<0.01	0.09	0.07	0.06	0.78

组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	TEG
组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	R/min	K/min	Angle角/°	MA/mm
病例组	120	5.98±4.38	1.12±1.07	5.28±0.86	1.98±0.68	65.95±6.84	63.17±8.02
对照组	30	1.23±0.11	0.45±0.09	5.63±1.03	2.15±0.38	63.05±8.02	62.79±6.08
t值		11.87	3.51	1.72	1.83	1.92	0.29
P值		<0.01	<0.01	0.09	0.07	0.06	0.78

组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	TEG
组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	R/min	K/min	Angle角/°	MA/mm
极高风险组	30	10.20±3.33^*#	1.70±1.62^*#	5.06±0.92	1.71±0.55	67.95±6.21	65.59±9.07
高风险组	30	8.50±3.93^*#	1.35±0.81^*	5.12±0.78	1.80±0.72	67.08±6.73	65.42±7.93
中风险组	40	2.75±1.33	0.89±0.71	5.25±0.83	2.07±0.58	65.77±6.26	61.62±8.28
低风险组	20	2.54±1.38	0.62±0.48	5.49±0.84	2.11±0.74	64.12±7.41	61.35±6.30
F值		61.87	7.44	1.19	2.50	2.19	2.48
P值		<0.01	<0.01	0.32	0.06	0.09	0.06

组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	TEG
组别	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	R/min	K/min	Angle角/°	MA/mm
极高风险组	30	10.20±3.33^*#	1.70±1.62^*#	5.06±0.92	1.71±0.55	67.95±6.21	65.59±9.07
高风险组	30	8.50±3.93^*#	1.35±0.81^*	5.12±0.78	1.80±0.72	67.08±6.73	65.42±7.93
中风险组	40	2.75±1.33	0.89±0.71	5.25±0.83	2.07±0.58	65.77±6.26	61.62±8.28
低风险组	20	2.54±1.38	0.62±0.48	5.49±0.84	2.11±0.74	64.12±7.41	61.35±6.30
F值		61.87	7.44	1.19	2.50	2.19	2.48
P值		<0.01	<0.01	0.32	0.06	0.09	0.06

肿瘤类型	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	TEG
肿瘤类型	例数	TAT/（ng·mL^-1）	PIC/（μg·mL^-1）	R/min	K/min	Angle角/°	MA/mm
肝癌	43	6.64±4.89	1.00±1.16	5.28±0.82	2.06±0.74	63.94±7.33	62.92±8.44
肺癌	29	6.30±4.37	1.41±1.07	5.24±1.07	1.86±0.74	66.96±7.61	64.40±9.37
肠癌	31	5.57±4.12	1.00±0.92	5.36±0.75	2.05±0.58	66.45±5.36	61.04±5.40
胃癌	17	4.52±3.19	1.14±1.06	5.15±0.85	1.67±0.54	68.34±5.63	65.56±8.16
F值		1.11	1.05	0.23	1.79	2.27	1.49
P值		0.35	0.37	0.88	0.15	0.09	0.22